Samsung Biologics Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial...

Related Keywords

South Korea ,Incheon ,Inch On Gwangyoksi ,New Jersey ,United States ,Samsung Biologics ,Samsung Bioepis ,Prnewswire Samsung Biologics ,Claire Kim ,Rd Center ,Samsung Life Science Fund ,Sustainable Market Initiative Terra Carta Seal ,Samsung Biologics Co Ltd ,Global Communications ,John Rim ,Araris Biotech ,Carbon Disclosure Project ,Sustainable Market Initiative ,Terra Carta Seal ,South San Francisco ,Biologics Contact ,